Member Info for Fruitsnveg

Spacman,

You're tying Prof Wilko's announcement (about putting together a collaborative pre-commercial consortium) with SNG001 being " the mainstay of the intervention trial/s". Which makes it altogether LESS LIKELY that Synairgen will need funding, because a pre-commercial consortium, if Synairgen is part of it, will dramatically reduce the amount they need to pay into the pot. That's how it works. A fundraise is not guaranteed. That is why is is an attractive model and no doubt why Prof Wilko is keen to get it up and running.

And yet, you invested 3 years ago because to your mind "it was a failure". Right.

DD, AZ in-licensed SNG001 as a novel therapy for viral-induced exacerbation in asthma in 2014 but Interim analysis revealed a lower-than-expected number of exacerbations would likely make it difficult to determine primary efficacy results.
To be clear, the drug did not fail; the trial (run by AZ) failed to harness a big enough number of exacerbations needed to determine efficacy.

2 rock solid points Tommy _D19. No response from Spacman though?
Maybe he has nil points left to give out.

It feels very much like you haven't reserched previous deals TFG have inserted themselves into Spacman? I would go do some rasearch. You could start with Arcam/GE, 2017. Quite straight forward exit strategy. No need for 'nil points' etc.

Synairgen has always ticked their 'under-valued and overlooked' box. I don't think their strategy has changed. Mid to long term investment. Wait. Let the science and data accumulate until an inflection point gives them an exit on the back of some attractive commercial deal that satisfies their price target. Pre-Sprinter their sweet spot was a ten fold increase, I think? Whatever it was in yesterday's post about their annual report.. I see no evidence from them that this strategy has changed (e.g. they seem OK with the BOD, no changes have been forced through).

I well aware TGF are familiar with SPACs. The SPAC you quote however was set up, according to it's SEC filing, to "target asset managers focused on investments in high-growth businesses generally, with a potential emphasis on technology and technology-enabled businesses." Like I said below, I can't see them making the decision to include Synairgen into one of their event-driven funds, only to then turn around and shove it into your 'SPAC machine'. That shows they had no investment strategy at the start, and we know that's not rue. And If Synairgen ever needs financing, it can find easier, less leaky, less time-consuming, less complicated and less risky ways to do it than via SPAC. Similarly for US listing. Synairgen don't "need" a SPAC. But I'm sure there are a few SPAC promoters that would "Love" Synairgen -> Fees-centrale. Am I right?

TGF didn't invest here using the strategy they did to see this out in a 'SPAC machine', that much I do know.
Unless you think they are complete clowns Spacman?

Mr Costs won't be banned for his disgustingly cruel comments, because Mr Costs doesn't exist. Just like countless other 'posters' on here. Just another fake account set up to feed the algorithm. Engagement, sentiment, algo, trading. That's what it's all about. Apparently.

"Our study sheds new light on the molecular interplay between SARS-CoV-2 and the host immune system, offering a foundation for the development of novel therapeutic strategies to combat COVID-19."

Thanks for posting link Alpha-Dog.

Object away Doc. Whatever rocks your boat.

I'm sure Axe can take a little ribbing Doc. It never seems to bother you when it's someone else was getting a pounding by him on here, you were looking so far the other way I often wondered how your head never fell off.
Lol. Shoe, foot, etc.

Were you back working at Walt Disney World Phoenix Axe? Which character did you play - Goofy or Donald Duck?
lol

JR90, Synairgen appear to be the only UK Biotech involved in the later conference (there are 2 coming up). To date no AZ, no GSK, no J&J, etc. The other 2 on the programme agenda with product are 1 from Germany and Shionogi (which is already on Strive), plus a number of non-commercial orgs, academic institutions, researchers and the like. The lack of other commercial respiratory pharmas/biotech co's, large or small, at that conference, raises an eyebrow IMHO. To me It looks like quite a deliberately focussed group? The programme agenda looks interesting.

Of course more funding being unlocked is a good thing, ridiculous to say it will have no effect on companies like Synairgen who are looking at multiple options. _> STRIVE will not be the only rodeo show in town when it comes to spending that $5 billion.

Thanks for the link both. It's great to see the support for new additional therapies is in not waning, or that the need for pandemic ready treatments has in no way gone away. Could this $5B program be in our future? I would hope so.

"“Project Next Gen” — the long-anticipated follow-up to “Operation Warp Speed,” the Trump-era program that sped coronavirus vaccines to patients in 2020 — would take a similar approach to partnering with private-sector companies to expedite development of vaccines and therapies. Scientists, public heath experts and politicians have called for the initiative, warning that existing therapies have steadily lost their effectiveness and that new ones are needed.
“It’s been very clear to us that the market on this is moving very slowly,” Ashish Jha, the White House coronavirus coordinator, said Monday. “There’s a lot that government can do, the administration can do, to speed up those tools … for the American people.”

Breakthrough scientific data is never old news Mani. You'll probably notice that we are doing a thematic poster session. That means posters are programmed together under one or several themes, did you notice? Authors are given a specific time to be present at their posters, when the viewers can discuss the work with them on a one-on-one or small group basis. It's a huge networking and commercial opportunity, as are all conferences at that level given the global reach of experts attending. Showcasing and networking are not "nice to haves". They are vital in this type of industry. It's a shame you don't understand the commercial importance.

Thanks for those nuggets of commercial wisdom there Mani. Was this inspired by your vast experience in the Biotech industry /as a CEO? What do you think RM should do instead of presenting "Clinical Development of Inhaled Interferon Beta-1a (SNG001) for the Treatment of Patients With COVID-19 in the Home and Hospital Settings" to an American audience about an American-sponsored trial to find treatments for Covid. Talk about the weather?
Dear me.

Ghia,
"we know we will need some form of dilution in the near future.". I don't see why that should be the case. There are several alternative ways of financing that avoid dilution, including out-licensing the grunt work to a BP. If the company does not want to give up all the upside then some hybrid license models can be used, e.g. two license partners can agree to co-develop and Synairgen keeps, for instance, the right to commercialise it a certain market like the UK, or Europe. If remaining cash and the proceeds from the license contract do not cover the development costs required, then the license contract can also for example be linked to an equity investment of the licensee. Other clauses like research funding or copromotion could equally facilitate the growth and development of Synairgen if such a clause were used. There are many clauses that allow structuring the license agreement to meet the financial and strategic needs of both parties, not simply one at the sacrifice of the other. IMO It is limiting to say at this point that "we will need some form of dilution in the near term". As I have outlined above, there are ways of avoiding this.

Ah yes, I recall you are invested in this 'other' treatment Mani, or 'ramping it to hell' as one of your compatriots here and fellow investors there so eloquently put it recently. You need more PI's to exit SNG and plough monies in there now, so you can ride that wave and make even your money on this other stock? I've been wondering why you so suddenly turned from chief Ramper here to chief Moaner on SNG? Of course, it is so you can make a buck elsewhere. I hope no one is suckered by your cunning ploy. For shame, Mani.